CS
CORT icon

Credit Suisse’s Corcept Therapeutics CORT Stock Holding History

Credit Suisse’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.27M Hold
129,621
– – ﹤0.01% 1551
2023
Q4 		$4.21M Buy
129,621
+9,018
+7% +$248K ﹤0.01% 1431
2023
Q3 		$3.29M Sell
120,603
-2,792
-2% -$80.8K ﹤0.01% 1529
2023
Q2 		$2.75M Sell
123,395
-24,292
-16% -$559K ﹤0.01% 1714
2023
Q1 		$3.2M Buy
147,687
+7,605
+5% +$167K ﹤0.01% 1597
2022
Q4 		$2.85M Buy
140,082
+31,754
+29% +$796K ﹤0.01% 1672
2022
Q3 		$2.78M Buy
108,328
+1,345
+1% +$36K ﹤0.01% 1634
2022
Q2 		$2.54M Sell
106,983
-12,019
-10% -$262K ﹤0.01% 1744
2022
Q1 		$2.68M Buy
119,002
+10,753
+10% +$229K ﹤0.01% 1880
2021
Q4 		$2.14M Sell
108,249
-7,138
-6% -$145K ﹤0.01% 2735
2021
Q3 		$2.27M Sell
115,387
-8,382
-7% -$175K ﹤0.01% 2728
2021
Q2 		$2.72M Buy
123,769
+18,701
+18% +$416K ﹤0.01% 2604
2021
Q1 		$2.5M Sell
105,068
-13,593
-11% -$363K ﹤0.01% 2644
2020
Q4 		$3.1M Buy
118,661
+36,086
+44% +$760K ﹤0.01% 2484
2020
Q3 		$1.44M Sell
82,575
-3,745
-4% -$59.7K ﹤0.01% 2667
2020
Q2 		$1.45M Sell
86,320
-4,347
-5% -$61.1K ﹤0.01% 2636
2020
Q1 		$1.08M Buy
90,667
+27,786
+44% +$344K ﹤0.01% 2599
2019
Q4 		$760K Sell
62,881
-8,383
-12% -$117K ﹤0.01% 3310
2019
Q3 		$1.01M Buy
71,264
+4,281
+6% +$52.6K ﹤0.01% 3011
2019
Q2 		$747K Sell
66,983
-6,616
-9% -$73.7K ﹤0.01% 3142
2019
Q1 		$865K Sell
73,599
-6,541
-8% -$81.3K ﹤0.01% 2997
2018
Q4 		$1.07M Sell
80,140
-52,393
-40% -$692K ﹤0.01% 2722
2018
Q3 		$1.86M Sell
132,533
-48,146
-27% -$673K ﹤0.01% 2404
2018
Q2 		$2.84M Buy
180,679
+24,417
+16% +$425K ﹤0.01% 2165
2018
Q1 		$2.57M Buy
156,262
+38,756
+33% +$718K ﹤0.01% 2220
2017
Q4 		$2.12M Buy
117,506
+3,066
+3% +$55.5K ﹤0.01% 2391
2017
Q3 		$2.21M Buy
114,440
+47,842
+72% +$713K ﹤0.01% 2466
2017
Q2 		$785K Buy
66,598
+22,040
+49% +$240K ﹤0.01% 2847
2017
Q1 		$488K Sell
44,558
-111,607
-71% -$980K ﹤0.01% 3302
2016
Q4 		$1.13M Buy
156,165
+83,805
+116% +$657K ﹤0.01% 2922
2016
Q3 		$470K Sell
72,360
-11,262
-13% -$65.5K ﹤0.01% 3454
2016
Q2 		$456K Buy
83,622
+61,946
+286% +$322K ﹤0.01% 3483
2016
Q1 		$102K Sell
21,676
-74,729
-78% -$291K ﹤0.01% 3824
2015
Q4 		$480K Buy
96,405
+44,145
+84% +$199K ﹤0.01% 3414
2015
Q3 		$196K Sell
52,260
-9,005
-15% -$45.7K ﹤0.01% 3935
2015
Q2 		$369K Buy
61,265
+34,560
+129% +$212K ﹤0.01% 3905
2015
Q1 		$150K Buy
26,705
+6,704
+34% +$24.3K ﹤0.01% 4152
2014
Q4 		$60K Buy
20,001
+6,536
+49% +$19.9K ﹤0.01% 4508
2014
Q3 		$36K Sell
13,465
-1,300
-9% -$3.44K ﹤0.01% 4369
2014
Q2 		$41K Sell
14,765
-34,519
-70% -$102K ﹤0.01% 4602
2014
Q1 		$215K Buy
49,284
+10,617
+27% +$37.1K ﹤0.01% 4310
2013
Q4 		$124K Buy
38,667
+26,377
+215% +$53.3K ﹤0.01% 4441
2013
Q3 		$19K Sell
12,290
-3,769
-23% -$6.65K ﹤0.01% 4180
2013
Q2 		$28K Buy
+16,059
New +$28.9K ﹤0.01% 4132

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Credit Suisse's CORT Position: Q1 2024 in Review

Credit Suisse held its Corcept Therapeutics (CORT) position steady in Q1 2024 at 129,621 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Credit Suisse first reported a position in CORT in Q2 2013 and has held it in 44 quarters since. The position peaked at $4.21M in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Credit Suisse held 129,621 shares of Corcept Therapeutics worth $3.27M as of Q1 2024.
  • Credit Suisse left its Corcept Therapeutics share count unchanged in Q1 2024.
  • Corcept Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1551 holding.
  • Credit Suisse first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Corcept Therapeutics position peaked at $4.21M in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.